Analyst Jason Gerberry of Bank of America Securities maintained a Buy rating on Fractyl Health, Inc. (GUTS – Research Report), with a price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Buy rating due to a combination of factors, primarily focusing on the promising data from Fractyl Health, Inc.’s Reveal-1 study. The open-label data showed that most patients either maintained or lost weight after discontinuing GLP1 therapy, which is a positive indicator for the company’s Revita treatment. This data is seen as reducing the risk for the upcoming pivotal Remain-1 study, which is expected to provide more comprehensive results in the third quarter.
Gerberry is particularly optimistic about the potential of the Remain-1 study, which will compare Revita against a sham control in a randomized controlled trial setting. The expectation is that Revita will show a significant advantage in weight maintenance following GLP1 discontinuation, with a target of a 50% better outcome compared to the sham. Given these factors, Gerberry maintains a Buy rating, anticipating that the upcoming data could significantly enhance the stock’s value.
Gerberry covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Liquidia Technologies, and Jazz Pharmaceuticals. According to TipRanks, Gerberry has an average return of 2.6% and a 49.38% success rate on recommended stocks.
In another report released on June 23, Canaccord Genuity also maintained a Buy rating on the stock with a $12.00 price target.